FMS - Fresenius Medical Care AG & Co. KGaA

NYSE - NYSE Delayed Price. Currency in USD
38.72
+0.06 (+0.16%)
At close: 4:02PM EDT

38.72 0.00 (0.00%)
After hours: 4:17PM EDT

Stock chart is not supported by your current browser
Previous Close38.66
Open38.56
Bid38.76 x 800
Ask38.76 x 800
Day's Range38.51 - 38.80
52 Week Range30.99 - 53.40
Volume162,084
Avg. Volume219,887
Market Cap23.485B
Beta (3Y Monthly)1.93
PE Ratio (TTM)10.49
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.63 (1.50%)
Ex-Dividend Date2019-05-17
1y Target EstN/A
Trade prices are not sourced from all markets
  • Moody's6 hours ago

    Fresenius Medical Care US Finance II, Inc -- Moody's announces completion of a periodic review of ratings of Fresenius Medical Care Holdings, Inc.

    Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Fresenius Medical Care Holdings, Inc. Frankfurt am Main, May 22, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Fresenius Medical Care Holdings, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.

  • Thomson Reuters StreetEvents10 days ago

    Edited Transcript of FME.DE earnings conference call or presentation 2-May-19 1:30pm GMT

    Q1 2019 Fresenius Medical Care AG & Co KGaA Earnings Call

  • Fresenius Medical (FMS) Q1 Earnings & Revenues Top Estimates
    Zacks16 days ago

    Fresenius Medical (FMS) Q1 Earnings & Revenues Top Estimates

    Fresenius Medical (FMS) gains from solid international revenues in Q1.

  • Reuters20 days ago

    Fresenius makes solid start to year after turbulent 2018

    Fresenius reported a rise in first-quarter sales and operating profit on Thursday, helped by growth at its generic infusion drugs and dialysis units, as its troubled German hospital business showed signs of stabilisation. Currency-adjusted quarterly sales rose 5 percent to 8.5 billion euros (£7.3 billion), helped by growth at its Kabi infusion unit and separately listed Fresenius Medical Care. "All four Fresenius business segments have developed in line with our expectations, putting us well on course to meet our targets for the year," Chief Executive Stephan Sturm said.

  • Fresenius Medical Care to pay $231M to resolve bribery charges
    American City Business Journals2 months ago

    Fresenius Medical Care to pay $231M to resolve bribery charges

    Fresenius Medical Care, a dialysis clinic operator, agreed Friday to pay $231 million in penalties to resolve allegations it paid bribes to win business deals in several countries, including Angola and Saudi Arabia.

  • Hedge Funds Have Never Been This Bullish On Fresenius Medical Care AG (FMS)?
    Insider Monkey2 months ago

    Hedge Funds Have Never Been This Bullish On Fresenius Medical Care AG (FMS)?

    Hedge fund managers like David Einhorn, Bill Ackman, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us with significant returns as well. Many hedge funds, like Paul Singer’s Elliott Management, are pretty secretive, but we can still get some insights by analyzing […]

  • Reuters2 months ago

    Fresenius Medical Care to pay $231 mln to resolve criminal, civil foreign bribery charges

    Germany-based dialysis clinic operator Fresenius Medical Care AG will pay about $231 million to resolve criminal and civil allegations that the company paid bribes to public health and government officials in several countries to win or retain business, the U.S. Justice Department said on Friday. The Justice Department agreed not to prosecute the company criminally in exchange for Fresenius paying a penalty of $84,715,273. The Securities and Exchange Commission, meanwhile, ordered the company to pay $147 million in disgorgement and prejudgment interest to settle the civil charges.

  • Reuters2 months ago

    Fresenius Medical Care says U.S. settlement will not affect 2019, 2020 results

    Fresenius Medical Care AG said that a $231.7 million U.S. settlement reached on Friday to resolve bribery allegations would have no impact on its 2019 and 2020 results because it had already made a financial ...

  • MarketWatch2 months ago

    Fresenius Medical Care to pay $231 million to settle bribery charges

    The Securities and Exchange Commission on Friday announced that Fresenius Medical Care AG & Co KGaA , a German medical device company, has agreed to pay over $231 million to settle charges brought by the Department of Justice and SEC. Fresenius was found to have violated the Foreign Corrupt Practices Act by falsifying documents as well as contracts and funneling bribes through third-party intermediaries. FMC paid nearly $30 million in bribes to government officials and others to procure business, the company said. "By engaging in widespread bribery schemes across multiple countries, the company prioritized profits over compliance in its dealings with foreign government officials," said Tracy Price, deputy chief of the SEC Enforcement Division's FCPA Unit, in a statement.

  • Fresenius Medical to Make Huge Investments, Competition Rife
    Zacks2 months ago

    Fresenius Medical to Make Huge Investments, Competition Rife

    Fresenius Medical (FMS) is likely to make huge investments in India and China.

  • Fresenius Medical's New Hemodialysis Software Gets FDA Nod
    Zacks2 months ago

    Fresenius Medical's New Hemodialysis Software Gets FDA Nod

    Fresenius Medical (FMS) offers a wide range of HD and PD dialysis products.

  • Baxter's (BAX) New Tie Up to Boost Acute Therapies Business
    Zacks2 months ago

    Baxter's (BAX) New Tie Up to Boost Acute Therapies Business

    Baxter's (BAX) Acute Therapies business is expected to grow 7-8% in 2019.

  • The Wall Street Journal2 months ago

    [$$] Fresenius Medical Care Readies for US Dialysis Shift

    , Secretary of the U.S. Department of Health and Human Services, said he wanted kidney-care to shift to a more value-based approach, favoring prevention and home care, and making transplants and artificial kidneys more accessible.

  • Should Value Investors Pick Fresenius Medical (FMS) Stock?
    Zacks2 months ago

    Should Value Investors Pick Fresenius Medical (FMS) Stock?

    Let's see if Fresenius Medical (FMS) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

  • How Much Of Fresenius Medical Care AG & Co. KGaA (ETR:FME) Do Institutions Own?
    Simply Wall St.2 months ago

    How Much Of Fresenius Medical Care AG & Co. KGaA (ETR:FME) Do Institutions Own?

    If you want to know who really controls Fresenius Medical Care AG & Co. KGaA (ETR:FME), then you'll have to look at the makeup of its share registry. Large companiesRead More...

  • Reuters3 months ago

    U.S. seeks to cut dialysis costs with more home care versus clinics

    The goal is to reduce the $114 billion paid by the U.S. government each year to treat chronic kidney disease and end-stage renal disease, a top area of spending. The U.S. Centers for Medicare and Medicaid Services (CMS), which provides Medicare health benefits to more than 55 million Americans, is looking at a trial payment design that would improve care in the early stages of kidney disease, increase access to kidney transplants and favor home dialysis over clinic-based treatment, CMS head Seema Verma told Reuters in an interview.

  • Fresenius Medical (FMS) Earnings Beat, Revenues Miss in Q4
    Zacks3 months ago

    Fresenius Medical (FMS) Earnings Beat, Revenues Miss in Q4

    Fresenius Medical (FMS) sees higher Q4 revenues in EMEA and Asia Pacific regions.

  • The Wall Street Journal3 months ago

    [$$] German Dialysis Firm Reaches Agreement in Bribery Probe

    German health-care firm Fresenius Medical Care AG said last week in a regulatory filing that it had reached an agreement in principle with U.S. authorities regarding a long-running foreign-bribery investigation that involved an anonymous whistleblower complaint. Fresenius said in the filing that it received communications beginning in 2012 that had alleged conduct outside the U.S. that might violate the Foreign Corrupt Practices Act or other antibribery laws. According to documents reviewed by The Wall Street Journal, an anonymous whistleblower sent an email in April 2012 to Fresenius managers and board members.

  • Reuters3 months ago

    FMC wraps up $2 bln acquisition of NxStage

    Germany's Fresenius Medical Care (FMC) wrapped up its $2 billion acquisition of U.S. home dialysis maker NxStage Medical on Friday, according to a U.S. Securities and Exchange Commission filing. The closure - some 18 months after FMC agreed to buy NxStage - paves the way for the world's biggest provider of dialysis services to scale up its home dialysis business by investing in new infrastructure, patient training and education.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of FME.DE earnings conference call or presentation 20-Feb-19 2:30pm GMT

    Q4 2018 Fresenius Medical Care AG & Co KGaA Earnings Call

  • Fresenius Medical Care AG & Co. (FMS) Q4 2018 Earnings Conference Call Transcript
    Motley Fool3 months ago

    Fresenius Medical Care AG & Co. (FMS) Q4 2018 Earnings Conference Call Transcript

    FMS earnings call for the period ending December 31, 2018.

  • FMC expects NxStage deal to close in next couple of days
    Reuters3 months ago

    FMC expects NxStage deal to close in next couple of days

    Germany's Fresenius Medical Care (FMC) said on Wednesday it has won the green light from U.S. regulators to acquire U.S. home dialysis equipment maker NxStage and expects the deal to close in the next few days. FMC agreed to buy NxStage in August 2017 for $2 billion but the deal has been held up due to competition concerns and most recently the U.S. government shutdown. "Very early this morning, we were notified the Federal Trade Commission has approved our NxStage deal," Chief Executive Rice Powell told reporters.

  • Reuters3 months ago

    Fresenius flags faster earnings growth from 2020 after investment

    Fresenius expects earnings to grow faster than sales from 2020 after investments to improve its German hospitals and scale up its home dialysis business eat up profit this year, the German healthcare group said on Wednesday. Investors, who were disappointed last year after the company trimmed its guidance in October and abandoned in 2020 targets in December, were heartened by the outlook and the prospect of a 7 percent increase in the dividend to 0.80 euros per share. "2019 will be a year of investment in growth areas such as home dialysis, biosimilars and new hospital services and therapies," Chief Executive Stefan Sturm said in a statement.